Tejara Capital Ltd Buys Shares of 38,537 Zymeworks Inc. (NYSE:ZYME)

Tejara Capital Ltd acquired a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,537 shares of the company's stock, valued at approximately $564,000. Tejara Capital Ltd owned 0.06% of Zymeworks as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. State Street Corp grew its position in shares of Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares in the last quarter. Barclays PLC grew its position in shares of Zymeworks by 476.3% during the third quarter. Barclays PLC now owns 154,384 shares of the company's stock worth $1,937,000 after purchasing an additional 127,595 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Zymeworks by 39.8% during the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company's stock worth $7,718,000 after purchasing an additional 175,000 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after purchasing an additional 311,107 shares in the last quarter. Finally, FMR LLC grew its position in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after purchasing an additional 1,525 shares in the last quarter. Institutional investors own 92.89% of the company's stock.

Remove Ads

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 320,690 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $11.49 per share, with a total value of $3,684,728.10. Following the purchase, the director now owns 16,040,851 shares of the company's stock, valued at approximately $184,309,377.99. The trade was a 2.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey T. L. Smith sold 11,110 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $165,761.20. Following the sale, the executive vice president now directly owns 8,890 shares of the company's stock, valued at $132,638.80. This represents a 55.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 1,507,168 shares of company stock worth $19,339,774 and sold 89,601 shares worth $1,336,847. Company insiders own 1.92% of the company's stock.

Zymeworks Price Performance

Shares of Zymeworks stock traded down $0.21 on Friday, reaching $12.72. The company had a trading volume of 800,233 shares, compared to its average volume of 475,000. The firm has a market cap of $885.02 million, a price-to-earnings ratio of -8.48 and a beta of 1.13. The firm's 50-day moving average price is $13.72 and its two-hundred day moving average price is $13.68. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Lifesci Capital assumed coverage on Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Wells Fargo & Company raised their price target on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. HC Wainwright raised their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Citigroup raised their price target on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target for the company in a report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $21.00.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.